Abstract
Tacrolimus is known to potentially lead to adverse events in recipients with diarrhoea and/or calcium channel blocker (CCB) co-administration. We report a renal transplant recipient who suffered from severe nephrotoxicity related to a toxic tacrolimus trough concentration in both conditions, diarrhoea and CCB co-administration, and with genotyped CYP3A system and P-glycoprotein (P-gp) polymorphisms. To our knowledge, this is the first case to be investigated for such polymorphisms. Clinicians should be reminded of the possibility of highly increased levels of tacrolimus in situations of diarrhoea and/or co-administration of CCBs. It also highlights the key role in tacrolimus pharmacokinetics of the CYP3A system and P-gp polymorphisms, and their influence in high-risk situations when enzyme activity is already affected by enterocyte damage due to diarrhoea and CCB competition.
Abbreviations
- CCB:
-
Calcium channel blocker
- CYP:
-
Cytochrome P450
- MDR1:
-
Multi-drug resistance 1
- P-gp:
-
P-glycoprotein
- SNP:
-
Single nucleotide polymorphism
References
Chow FS, Jusko WJ (2004) Immunosuppressive interactions among calcium channel antagonists and selected corticosteroids and macrolides using human whole blood lymphocytes. Drug Metab Pharmacokinet 19:413–421
Herbert MF (1997) Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 15:201–214
Maezono S, Sugimoto K, Sakamoto K, Ohmori M, Hishikawa S, Mizuta K, Kawarasaki H, Watanabe Y, Fujimura A (2005) Elevated blood concentrations of calcineurin inhibitors during diarrheal episode in pediatric liver transplant recipients: involvement of the suppression of intestinal cytochrome P450 3A and P-glycoprotein. Pediatr Transplant 9:315–323
Daly AK (2006) Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet 45:13–31
Utecht KN, Hiles JJ, Kolesar J (2006) Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors. Am J Health Syst Pharm 63:2340–2348
Hebert MF, Lam AY (1999) Diltiazem increases tacrolimus concentrations. Ann Pharmacother 33:680–682
Sato K, Amada N, Sato T, Miura S, Ohashi Y, Sekiguchi S, Satomi S, Okazaki H (2004) Severe elevations of FK506 blood concentration due to diarrhea in renal transplant recipients. Clin Transplant 18:585–590
Fitts SW, Green M, Reyes J, Nour B, Tzakis AG, Kocoshis SA (1995) Clinical features of nosocomial rotavirus infection in pediatric liver transplant recipients. Clin Transplant 9:201–204
Eades SK, Boineau FG, Christensen ML (2000) Increased tacrolimus levels in a pediatric renal transplant patient attributed to chronic diarrhea. Pediatr Transplant 4:63–66
Lampen A, Christians U, Gonschior AK, Bader A, Hackbarth I, von Engelhardt W, Sewing KF (1996) Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber. Br J Pharmacol 117:1730–1734
Mittal N, Thompson JF, Kato T, Tzakis AG (2001) Tacrolimus and diarrhea: pathogenesis of altered metabolism. Pediatr Transplant 5:75–79
Van der Schaaf MR, Hene RJ, Floor M, Blankestijn PJ, Koomans HA (1995) Hypertension after renal transplantation. Calcium channel or converting enzyme blockade? Hypertension 25:77–81
Ruggenenti P, Perico N, Mosconi L, Gaspari F, Benigni A, Amuchastegui CS, Bruzzi I, Remuzzi G (1993) Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 43:706–711
Chrysostomou A, Walker RG, Russ GR, d'Apice AJ, Kincaid-Smith P, Mathew TH (1993) Diltiazem in renal allograft recipients receiving cyclosporine. Transplantation 55:300–304
Krahenbuhl S, Menafoglio A, Giostra E, Gallino A (1998) Serious interaction between mibefradil and tacrolimus. Transplantation 66:1113–1115
Ocran KW, Plauth M, Mai I, Lochs H (1999) Tacrolimus toxicity due to drug interaction with mibefradil in a patient after liver transplantation. Z Gastroenterol 37:1025–1028
Pallet N, Bouvier N, Bendjallabah A, Rabant M, Flinois JP, Hertig A, Legendre C, Beaune P, Thervet E, Anglicheau D (2008) Cyclosporine-induced endoplasmic reticulum stress triggers tubular phenotypic changes and death. Am J Transplant 8:2283–2296
Chowbay B, Li H, David M, Cheung YB, Lee EJ (2005) Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol 60:159–171
Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383–391
Fukudo M, Yano I, Yoshimura A, Masuda S, Uesugi M, Hosohata K, Katsura T, Ogura Y, Oike F, Takada Y, Uemoto S, Inui K (2008) Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics 18:413–423
Goto M, Masuda S, Saito H, Uemoto S, Kiuchi T, Tanaka K, Inui K (2002) C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 12:451–457
Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ (2003) Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 13:89–95
Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, van Gelder T (2003) Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74:245–254
Op den Buijsch RA, Christiaans MH, Stolk LM, de Vries JE, Cheung CY, Undre NA, van Hooff JP, van Dieijen-Visser MP, Bekers O (2007) Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol 21:427–435
Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y (2007) CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 82:711–725
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Leroy, S., Isapof, A., Fargue, S. et al. Tacrolimus nephrotoxicity: beware of the association of diarrhea, drug interaction and pharmacogenetics. Pediatr Nephrol 25, 965–969 (2010). https://doi.org/10.1007/s00467-009-1402-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-009-1402-8